US4812557A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Stable composition of interleukin-2 and human serum albumin
Assignee: Takeda Pharmaceutical Co Ltd
•
Filing: 1986-11-17
•
Granted: 1989-03-14
•
Expires: 2006-11-17
Abstract
Abstract The present invention provides an interleukin-2 composition which comprises human serum albumin, a reducing compound or a combination thereof and is adjusted as showing pH of 3 to 6 as a solution. The composition of the present invention is characterized in that interleukin-2 activity is minimized during storage and in the processes of freezing and lyophilization.
Inventors
- 👤 Mikura Yasushi
- 👤 Asada Kensuke
- 👤 Toguchi Hajime
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-31 20:17
CPC Classifications
A; A61; A61K; A61K38/00; A61K38/16; A61K47/00; A61K47/30; A61K47/42; A61K38/17; A61K38/19; A61K38/20; A61K38/2013; A61K47/06; A61K47/16; A61K47/18; A61K47/183; A61K9/00; A61K9/0012; A61K9/0019; A61K9/14; A61K9/19; Y; Y10; Y10S; Y10S435/00; Y10S435/8215; Y10S435/948; Y10S530/00; Y10S530/827; Y10S530/828; Y10S930/00; Y10S930/01; Y10S930/14; Y10S930/141
Claims Analysis
Total Claims: 16
Claim 1
Independent Claim
51 words
A human interleukin-2 composition in the form of an aqueous solution or frozen matter which comprises in addition to human interleukin-2, human serum albumin in a concentration of about 0.1 to 50 mg/ml as an aqueous solution, and, as a solution, is adjusted to have a pH between 3 to 5.5.
Claim 2
Dependent Claim
51 words
A human interleukin-2 composition in the form of an aqueous solution or frozen matter which comprises in addition to human interleukin-2, human serum albumin in a concentration of about 0.1 to 50 mg/ml as an aqueous solution, and, as a solution, is adjusted to have a pH between 3 to 5.5.
Claim 3
Dependent Claim
15 words
The composition according to claim 1, wherein the human interleukin-2 is a recombinant human interleukin-2.
Claim 4
Dependent Claim
15 words
The composition according to claim 1, wherein the human interleukin-2 is a non-glycosylated human interleukin-2.
Claim 5
Dependent Claim
19 words
The composition according to claim 1, wherein the human interleukin-2 has a specific activity of 20,000 to 80,000 units/mg.
Claim 6
Dependent Claim
23 words
The composition according to claim 1, wherein the human interleukin-2 is in a concentration of 1 to 80,000 units/ml as an aqueous solution.
Claim 7
Dependent Claim
12 words
The composition according to claim 1, which is free from a salt.
Claim 8
Dependent Claim
27 words
The composition according to claim 1, which further comprises a monoamino aliphatic amino acid, a cyclic amino acid, a monosaccharide, a sugar alcohol or a combination thereof.
Claim 9
Dependent Claim
14 words
The composition according to claim 1, which further comprises a monoamino aliphatic amino acid.
Claim 10
Dependent Claim
25 words
The composition according to claim 8, wherein the monoamino aliphatic amino acid is in a concentration of 5 to 50 mg/ml as an aqueous solution.
Claim 11
Dependent Claim
32 words
The composition according to claim 1, wherein the pH of the composition is adjusted by an acidic reducing compound, an acidic amino acid, a mineral acid or/and a buffer of organic acid.
Claim 12
Dependent Claim
28 words
The composition according to claim 7, wherein the additional component is a monosaccharide, a sugar alcohol or a combination thereof in a concentration of 10 to 100 mg/ml.
Claim 13
Dependent Claim
18 words
The composition according to claim 1, comprising a combination of the human serum albumin and a reducing compound.
Claim 14
Dependent Claim
15 words
The composition according to claim 12, wherein the reducing compound is an acidic reducing compound.
Claim 15
Dependent Claim
27 words
The composition according to claim 13, wherein the acidic reducing compound is glutathione, thioctic acid, N-acetylcysteine, thioalkanoic acid of 1 to 7 carbon atoms or ascorbic acid.
Claim 16
Dependent Claim
21 words
The composition according to claim 12, wherein the reducing compound is in a concentration of 0.05-20 mg/ml as an aqueous solution.
References Cited (Backward Citations)
US4508833A
Cited
EP0091258A2
Cited
FR2532178A1
Cited
US4490289A
Cited
EP0145390A2
Cited
US4530787A
Cited
US4569790A
Cited
US4604377A
Cited
US4530787B1
Cited
US4645830A
Cited
US4572798A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1992-03-13 | 1992-09-12 | 1993-03-14 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1996-03-13 | 1996-09-12 | 1997-03-14 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2000-03-13 | 2000-09-12 | 2001-03-14 | $7700.00 | Window Closed / Lapsed |